Gland Pharma. a generic injectable focused pharmaceutical company, received tentative approval from the United States Food and Drug Administration (USFDA),  for Cangrelor for Injection, 50 mg/vial Single-Dose Vials.

Gland Pharma believes that they are amongst one of the first to file for this product and may be eligible for 180 days of generic drug exclusivity.

Gland Pharma will launch the product with its marketing partner on receipt of final approval.